요폐 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 7.3%의 연평균 성장률(CAGR)로 47억 5,000만 달러에 달할 것으로 전망됩니다. 예측 기간 동안의 성장 전망은 재택의료 수요 증가, 전립선암 환자 수 증가, 최소침습 수술에 대한 수요 증가, 연구 이니셔티브 증가, 노인 인구 증가 등에 기인합니다. 예측 기간 동안 예상되는 주요 동향으로는 새롭고 혁신적인 치료 옵션의 개발, 요실금 장치의 발전, 기술 혁신, 전략적 파트너십 및 제휴, 침습적 OTC 장치의 부상, 웨어러블 기술의 성장 등이 있습니다.
전립선암 발병률의 증가는 예측 기간 동안 전립선암 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 전립선암은 전립선에서 통제할 수 없는 세포 증식을 특징으로 하는 악성 질환입니다. 전립선암 환자의 증가는 주로 인구통계학적 변화로 인해 고령 남성의 증가에 기인합니다. 인구가 고령화됨에 따라 전립선암을 포함한 노화 관련 질환의 발병 위험이 증가합니다. 전립선암 환자에게 요폐 치료제는 필수적입니다. 종양이나 비대해진 전립선이 요도를 막고 배뇨를 방해해 소변이 잘 나오지 않아 소변의 흐름을 정상으로 되돌릴 수 있는 치료가 필요하기 때문입니다. 예를 들어, 2024년 6월 미국 질병예방통제센터(CDC)는 2022년 미국 내 남성 3만 3,363명이 전립선암으로 사망하고 2021년에는 23만 6,659명이 전립선암으로 새로 진단받았다고 보고했습니다. 이에 따라 전립선암 발병률 증가가 전립선암 치료제 수요를 견인할 것으로 예상됩니다.
요폐 치료제 시장의 주요 기업들은 방광과 장의 조절을 개선하기 위해 차세대 천골신경자극요법과 같은 첨단 기술에 집중하고 있습니다. 천골신경자극요법은 가벼운 전기 자극으로 천골신경을 자극하여 요폐 및 과민성 방광의 증상을 완화합니다. 예를 들어, 2022년 2월 아일랜드에 본사를 둔 의료기기 기업 Medtronic Plc는 미국 식품의약국(FDA)으로부터 InterStim X 시스템의 승인을 받아 맞춤형 천골신경자극요법에 큰 진전을 이루었습니다. 배터리, MRI 지원, 맞춤형 치료를 위한 스마트 프로그래머가 특징입니다. 또한, 2단계 이식 과정을 통해 영구적 이식 전에 시험 기간을 가질 수 있습니다. InterStim 시스템은 충전이 필요 없는 InterStim X와 충전식 InterStim Micro의 두 가지 장기 옵션으로 제공되며, 과민성 방광 및 만성 요실금과 같은 증상에 맞게 설계되어 있습니다. 설계되어 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 요폐 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 요폐 치료제 시장 : 성장률 분석
- 세계의 요폐 치료제 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 요폐 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 요폐 치료제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 요폐 치료제 시장 : 약물 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 5α환원효소 억제제·α차단제
- 항콜린제 또는 항경련제
- 항우울제
- 골격근 이완제
- 국소 에스트로겐
- 기타
- 세계의 요폐 치료제 시장 : 요실금 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 복압성 요실금
- 절박성 요실금
- 일류성 요실금
- 혼합성 요실금
- 기타
- 세계의 요폐 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 경구
- 방광내
- 정맥내
- 경피
- 세계의 요폐 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 소매 약국
- 병원 약국
- 온라인 약국
- 세계의 요폐 치료제 시장 : 5α 환원효소 억제제·α 차단제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 피나스테리드
- 두타스테리드
- 탐술로신
- 알푸조신
- 테라조신
- 독사조신
- 세계의 요폐 치료제 시장 : 항콜린제 또는 항경련제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 옥시부티닌
- 톨테로딘
- 솔리페나신
- 다리페나신
- 트로스피움
- 페소테로딘
- 세계의 요폐 치료제 시장 : 항우울제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 이미프라민
- 아미트립틸린
- 둘록세틴
- 세계의 요폐 치료제 시장 : 골격근 이완제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 바클로펜
- 티자니딘
- 디아제팜
- 시클로벤자프린
- 세계의 요폐 치료제 시장 : 국소 에스트로겐 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 에스트라디올 크림
- 공액 에스트로겐
- 에스트리올 질 크림
- 세계의 요폐 치료제 시장 : 기타 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 보툴리눔톡신(보톡스)
- 미라베그론
- 데스모프레신
제7장 지역별·국가별 분석
- 세계의 요폐 치료제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 요폐 치료제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 요폐 치료제 시장 : 경쟁 구도
- 요폐 치료제 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- GlaxoSmithKline Plc.
- Medtronic Plc
- Eli Lilly and Company
- Boston Scientific Corp.
- Sumitomo Pharma Inc.
- Ipsen Pharma
- Coloplast A/S
- Dr. Reddy's Laboratories
- Cipla Limited
- Amneal Pharmaceuticals Inc.
- Ferring Pharmaceuticals
- Otsuka Pharmaceutical Co. Ltd.
- NYMOX CORPORATION
- Antev Ltd.
- Amber Therapeutics
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 요폐 치료제 시장 2029 : 새로운 기회를 제공하는 국가
- 요폐 치료제 시장 2029 : 새로운 기회를 제공하는 부문
- 요폐 치료제 시장 2029 : 성장 전략
제36장 부록
ksm
Urinary retention therapeutics encompass a range of medical treatments designed to address the inability to fully empty the bladder. These therapies aim to relieve bladder pressure, restore normal urinary flow, and prevent complications such as infections or kidney damage. The primary objective is to improve bladder function and enhance the patient's comfort and overall quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main urinary retention therapeutics include 5-alpha-reductase inhibitors and alpha-blocker drugs, anticholinergic or antispasmodic agents, antidepressants, skeletal muscle relaxants, topical estrogens, and others. 5-alpha-reductase inhibitors and alpha-blocker drugs are commonly used to treat benign prostatic hyperplasia (BPH). The former works by reducing prostate size through blocking the hormone dihydrotestosterone (DHT), while the latter helps relax muscle fibers in the prostate and bladder neck to improve urine flow. These treatments are used for conditions such as stress incontinence, urge incontinence, overflow incontinence, mixed incontinence, and others. They are administered through various routes, including oral, intravesical, intravenous, and transdermal, and are distributed through channels such as retail pharmacies, hospital pharmacies, and online pharmacies.
The urinary retention therapeutics market research report is one of a series of new reports from The Business Research Company that provides urinary retention therapeutics market statistics, including urinary retention therapeutics industry global market size, regional shares, competitors with a urinary retention therapeutics market share, detailed urinary retention therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the urinary retention therapeutics industry. This urinary retention therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urinary retention therapeutics market size has grown strongly in recent years. It will grow from$3.33 billion in 2024 to $3.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historical period can be attributed to the rising incidence of urological disorders, increased healthcare spending, a growing global geriatric population, a higher prevalence of urinary incontinence (UI), and an escalating risk of related urological conditions among individuals.
The urinary retention therapeutics market size is expected to see strong growth in the next few years. It will grow to$4.75 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The projected growth during the forecast period can be attributed to the increasing demand for home-based care, a rising number of prostate cancer cases, growing demand for minimally invasive procedures, an increase in research initiatives, and a larger geriatric population. Key trends expected in the forecast period include the development of new and innovative treatment options, the advancement of urinary incontinence devices, technological innovations, strategic partnerships and collaborations, the rise of invasive OTC devices, and the growth of wearable technologies.
The growing incidence of prostate cancer is expected to drive the expansion of the urinary retention therapeutics market during the forecast period. Prostate cancer is a malignant condition characterized by uncontrolled cell growth in the prostate gland. The rise in prostate cancer cases is primarily due to demographic changes, with more men living longer lives. As the population ages, the risk of developing age-related diseases, including prostate cancer, naturally increases. Urinary retention therapeutics are vital for prostate cancer patients because the tumor or an enlarged prostate can block the urethra, making urination difficult and requiring treatments to restore normal urine flow. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that 33,363 men in the United States died from prostate cancer in 2022, while 236,659 new cases were diagnosed in 2021. Consequently, the growing number of prostate cancer cases will drive the demand for urinary retention therapeutics.
Key companies in the urinary retention therapeutics market are focusing on advanced technologies, such as next-generation sacral nerve stimulation therapy, to improve bladder and bowel control. Sacral nerve stimulation therapy uses mild electrical impulses to stimulate the sacral nerves, helping relieve symptoms of urinary retention or overactive bladder. For instance, in February 2022, Medtronic Plc, an Ireland-based medical device company, received approval from the U.S. Food and Drug Administration (FDA) for its InterStim X system, marking a significant advancement in personalized sacral nerve stimulation therapy. The InterStim X system features a long-lasting, recharge-free battery, MRI compatibility, and a smart programmer for tailored therapy. Its two-stage implantation process allows for a trial period before permanent placement. These innovations enhance the convenience and safety of managing bladder and bowel control. The InterStim systems offer two long-term options: the recharge-free InterStim X and the rechargeable InterStim Micro, both designed for conditions such as overactive bladder and chronic fecal incontinence.
In September 2023, Caldera Medical, a U.S.-based medical device company specializing in women's health, acquired Atlantic Therapeutics for an undisclosed amount. This acquisition allows Caldera Medical to expand its women's health portfolio by integrating the FDA-cleared Innova product family, which provides non-invasive treatments for stress urinary incontinence (SUI). Atlantic Therapeutics, an Ireland-based medical technology company, focuses on bladder control treatments, aligning with the urinary retention therapeutics market.
Major players in the urinary retention therapeutics market are Pfizer Inc., Merck KGaA, Abbvie Inc., Bayer AG, Sanofi SA, GlaxoSmithKline Plc., Medtronic Plc, Eli Lilly and Company, Boston Scientific Corp., Sumitomo Pharma Inc., Ipsen Pharma, Coloplast A/S, Dr. Reddy's Laboratories, Cipla Limited, Amneal Pharmaceuticals Inc., Ferring Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., NYMOX CORPORATION, Antev Ltd., Amber Therapeutics, Implantica Patent Ltd.
North America was the largest region in the urinary retention therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in urinary retention therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the urinary retention therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The urinary retention therapeutics market consists of revenues earned by entities by providing services such as drug development and formulation services, clinical trial management, regulatory consulting and medical device integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary retention therapeutics market also includes sales of catheters, prostate shrinking agents, urethral stents and sacral neuromodulation devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Urinary Retention Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on urinary retention therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for urinary retention therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary retention therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs; Anticholinergic Or Antispasmodic Agents; Antidepressants; Skeletal Muscle Relaxants; Topical Estrogens; Other Drugs
- 2) By Incontinence Type: Stress Incontinence; Urge Incontinence; Over-Flow Incontinence; Mixed Incontinence; Other Incontinence Types
- 3) By Administration Route: Oral; Intravesical; Intravenous; Transdermal
- 4) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
- Subsegments:
- 1) By 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs: Finasteride; Dutasteride; Tamsulosin; Alfuzosin; Terazosin; Doxazosin
- 2) By Anticholinergic or Antispasmodic Agents: Oxybutynin; Tolterodine; Solifenacin; Darifenacin; Trospium; Fesoterodine
- 3) By Antidepressants: Imipramine; Amitriptyline; Duloxetine
- 4) By Skeletal Muscle Relaxants: Baclofen; Tizanidine; Diazepam; Cyclobenzaprine
- 5) By Topical Estrogens: Estradiol Cream; Conjugated Estrogens; Estriol Vaginal Cream
- 6) By Other Drugs: Botulinum Toxin (Botox); Mirabegron; Desmopressin
- Companies Mentioned: Pfizer Inc.; Merck KGaA; Abbvie Inc.; Bayer AG; Sanofi SA
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Urinary Retention Therapeutics Market Characteristics
3. Urinary Retention Therapeutics Market Trends And Strategies
4. Urinary Retention Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Urinary Retention Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Urinary Retention Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Urinary Retention Therapeutics Market Growth Rate Analysis
- 5.4. Global Urinary Retention Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Urinary Retention Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Urinary Retention Therapeutics Total Addressable Market (TAM)
6. Urinary Retention Therapeutics Market Segmentation
- 6.1. Global Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs
- Anticholinergic Or Antispasmodic Agents
- Antidepressants
- Skeletal Muscle Relaxants
- Topical Estrogens
- Other Drugs
- 6.2. Global Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Stress Incontinence
- Urge Incontinence
- Over-Flow Incontinence
- Mixed Incontinence
- Other Incontinence Types
- 6.3. Global Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravesical
- Intravenous
- Transdermal
- 6.4. Global Urinary Retention Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- 6.5. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of 5-Alpha-Reductase Inhibitor And Alpha-Blocker Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Finasteride
- Dutasteride
- Tamsulosin
- Alfuzosin
- Terazosin
- Doxazosin
- 6.6. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Anticholinergic or Antispasmodic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oxybutynin
- Tolterodine
- Solifenacin
- Darifenacin
- Trospium
- Fesoterodine
- 6.7. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Imipramine
- Amitriptyline
- Duloxetine
- 6.8. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Skeletal Muscle Relaxants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Baclofen
- Tizanidine
- Diazepam
- Cyclobenzaprine
- 6.9. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Topical Estrogens, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Estradiol Cream
- Conjugated Estrogens
- Estriol Vaginal Cream
- 6.10. Global Urinary Retention Therapeutics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Botulinum Toxin (Botox)
- Mirabegron
- Desmopressin
7. Urinary Retention Therapeutics Market Regional And Country Analysis
- 7.1. Global Urinary Retention Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Urinary Retention Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Urinary Retention Therapeutics Market
- 8.1. Asia-Pacific Urinary Retention Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Urinary Retention Therapeutics Market
- 9.1. China Urinary Retention Therapeutics Market Overview
- 9.2. China Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Urinary Retention Therapeutics Market
- 10.1. India Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Urinary Retention Therapeutics Market
- 11.1. Japan Urinary Retention Therapeutics Market Overview
- 11.2. Japan Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Urinary Retention Therapeutics Market
- 12.1. Australia Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Urinary Retention Therapeutics Market
- 13.1. Indonesia Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Urinary Retention Therapeutics Market
- 14.1. South Korea Urinary Retention Therapeutics Market Overview
- 14.2. South Korea Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Urinary Retention Therapeutics Market
- 15.1. Western Europe Urinary Retention Therapeutics Market Overview
- 15.2. Western Europe Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Urinary Retention Therapeutics Market
- 16.1. UK Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Urinary Retention Therapeutics Market
- 17.1. Germany Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Urinary Retention Therapeutics Market
- 18.1. France Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Urinary Retention Therapeutics Market
- 19.1. Italy Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Urinary Retention Therapeutics Market
- 20.1. Spain Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Urinary Retention Therapeutics Market
- 21.1. Eastern Europe Urinary Retention Therapeutics Market Overview
- 21.2. Eastern Europe Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Urinary Retention Therapeutics Market
- 22.1. Russia Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Urinary Retention Therapeutics Market
- 23.1. North America Urinary Retention Therapeutics Market Overview
- 23.2. North America Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Urinary Retention Therapeutics Market
- 24.1. USA Urinary Retention Therapeutics Market Overview
- 24.2. USA Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Urinary Retention Therapeutics Market
- 25.1. Canada Urinary Retention Therapeutics Market Overview
- 25.2. Canada Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Urinary Retention Therapeutics Market
- 26.1. South America Urinary Retention Therapeutics Market Overview
- 26.2. South America Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Urinary Retention Therapeutics Market
- 27.1. Brazil Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Urinary Retention Therapeutics Market
- 28.1. Middle East Urinary Retention Therapeutics Market Overview
- 28.2. Middle East Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Urinary Retention Therapeutics Market
- 29.1. Africa Urinary Retention Therapeutics Market Overview
- 29.2. Africa Urinary Retention Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Urinary Retention Therapeutics Market, Segmentation By Incontinence Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Urinary Retention Therapeutics Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Urinary Retention Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Urinary Retention Therapeutics Market Competitive Landscape
- 30.2. Urinary Retention Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
31. Urinary Retention Therapeutics Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline Plc.
- 31.2. Medtronic Plc
- 31.3. Eli Lilly and Company
- 31.4. Boston Scientific Corp.
- 31.5. Sumitomo Pharma Inc.
- 31.6. Ipsen Pharma
- 31.7. Coloplast A/S
- 31.8. Dr. Reddy's Laboratories
- 31.9. Cipla Limited
- 31.10. Amneal Pharmaceuticals Inc.
- 31.11. Ferring Pharmaceuticals
- 31.12. Otsuka Pharmaceutical Co. Ltd.
- 31.13. NYMOX CORPORATION
- 31.14. Antev Ltd.
- 31.15. Amber Therapeutics
32. Global Urinary Retention Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Urinary Retention Therapeutics Market
34. Recent Developments In The Urinary Retention Therapeutics Market
35. Urinary Retention Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Urinary Retention Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Urinary Retention Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Urinary Retention Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r35005_Urinary_Retention_Therapeutics_GMR_2025
